ClinicalTrials.gov
ClinicalTrials.gov Menu

Prokinecitine in Acute Myocardial Infarction (Prok-Idm)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02021487
Recruitment Status : Recruiting
First Posted : December 27, 2013
Last Update Posted : September 11, 2017
Sponsor:
Information provided by (Responsible Party):
University Hospital, Strasbourg, France

Brief Summary:
The study aims to investigate the presence of a substance in the blood called prokinecitine, which is released by the heart when a heart attack occurs. Several venous blood samples at the arm are withdrawn at admission, H6, H12, H24, H48 and H72 in order to measure the concentration of this substance in the blood. The usefulness of this new blood marker is going to be determsined to seek if it would be of help to better diagnose or estimate the gravity of heart infarction after a heart attack.

Condition or disease
ST Elevatation Myocardial Infarction (STEMI)

Study Type : Observational
Estimated Enrollment : 200 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Pilot Study Prok-Idm: Interest of Dosage of Prokinecitine in Acute Myocardial Infarction
Actual Study Start Date : November 2013
Estimated Primary Completion Date : November 2019
Estimated Study Completion Date : November 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Attack




Primary Outcome Measures :
  1. Infarct size by MRI necrotic myocardial mass [ Time Frame: 7 days ]
    Infarct size by MRI necrotic myocardial mass



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with acute St elevation myocardial infarction of less than 6 hours
Criteria

Inclusion Criteria:

  • Patients with acute St elevation myocardial infarction of less than 6 hours
  • Age>18 y/o

Exclusion Criteria:

  • Previous myocardial infarction
  • LBB, RBB
  • Renal Insuffiency MDRD<30 mL/min
  • Patient with Pace-Maker or ICD.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02021487


Contacts
Contact: Patrick OHLMANN, MD 03 69 55 09 53 ext 0033 patrick.ohlmann@chru-strasbourg.fr

Locations
France
University Hospital Recruiting
Strasbourg, France, 67000
Contact: Patrick OHLMANN, MD         
Principal Investigator: Patrick OHLMANN, MD         
Sponsors and Collaborators
University Hospital, Strasbourg, France
Investigators
Principal Investigator: Patrick OHLMANN, MD University Hospital, Strasbourg, France

Responsible Party: University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier: NCT02021487     History of Changes
Other Study ID Numbers: 5515
First Posted: December 27, 2013    Key Record Dates
Last Update Posted: September 11, 2017
Last Verified: September 2017

Additional relevant MeSH terms:
Infarction
Myocardial Infarction
Ischemia
Pathologic Processes
Necrosis
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases